Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
A risk-management assessment of visible-residue limits (VRL) in cleaning validation of pharmaceutical formulations was conducted for both pharmaceutical pilot plant and manufacturing facilities. The authors discuss how potential risks were identified, analyzed for probability, considered for seriousness, and controlled through avoidance or mitigation. These opportunities for VRL implementation then were identified for both pilot plant and manufacturing settings.

Pharmaceutical Technology

10. R.J. Forsyth et al. "Correlation of Visible Residue Limits with Swab Results for Cleaning Validation," Pharm. Technol., in-press.

11. European Commission, "Qualification and Validation," EudraLex, Medicinal Products for Human and Veterinary Use: Good Manufacturing Practice, Vol. 4, Annex 15 (European Commission, Brussels, Belgium, July 2001).

12. Pharmaceutical Inspection Cooperation Scheme (PIC/S), Recommendations on Validation Master Plan, Installation and Operational Qualification, Non-Sterile Process Validation, Cleaning Validation, (PIC/S, Geneva, Switzerland, August 2002).

13. Health Canada, Health Products and Food Branch Inspectorate, "Cleaning Validation Guidelines" (Health Canada, Ottawa, Ontario, Canada, June 2002).

14. R. Sharnez, et al., "In Situ Monitoring of Soil Dissolution Dynamics: A Rapid and Simple Method for Determining Worst-Case Soils for Cleaning Validation," PDA J. Pharm. Sci. and Technol. 58 (4), 203-214 (2004).

Richard Forsyth* is an associate director in global clinical GMP quality with Merck & Co., Inc, WP53C-307, West Point, PA 19486, tel. 215.652.7462, fax 215.652.7106,
Jeffrey Hartman** is a validation manager in regulatory and analytical sciences with Merck & Co., Inc., WP97B-120, West Point, PA 19486, tel. 215.652.8101, fax 215.652.3314,
and Vince Van Nostrand is a research chemist in medicinal chemistry with Merck and Co., Inc.

*To whom pilot-plant correspondence should be addressed.

** To whom manufacturing correspondence should be addressed.

Submitted: May 16, 2006. Accepted: June 21, 2006.

Keywords: cleaning, inspection, risk management, validation, visible residue limit, VRL


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here